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Increased Bile Duct Complications and/or Chronic Rejection in 
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A.J. Demetris, S. Todo, J.J. Fung, and T.E. Starzl 
B ILE duct complications continue to be a significant 
cause of bile morbidity after orthotopic liver trans-
plantation, with an incidence of 7% to 34% of patients. 1•2 
Bile of duct obstruction, usually due to strictures, biliary 
leakage, and/or cholangitis, accounts for the majority of 
these complications. In contrast. although low incidence of 
chronic rejection has been reported under FK 506-based 
immunosuppression in early trials of liver transplantation,) 
chronic rejection after liver transplantation occurs in only 
5% to 9% of cases. and it remains one of the most common 
causes of graft lossK~·R There have been many conflicting 
recent reports concerning a relationship between the bile 
duct-related complications or ductopenic chronic rejection 
and a positive crossmatch.6 - s. We investigated the outcome 
of liver grafts from positive crossmatch donors. focusing on 
biliary complications and ductopenic chronic rejection, and 
we compared the results to a consecutive negative cross-
match control group at the same time. 
CASE MATERIALS 
We analyzed 306 consecutive adults (more than 16 years of 
age) primary liver transplant cases performed at Presbyte-
rian University Hospital in Pittsburgh between November 
13, 1989. and September 26. 1990. Twenty-eight (9.1%) 
patients were from a donor whose crossmatch test results 
were positive (more than 50% of donor lymphocytes were 
killed by dithiothreitol-pretreated recipient serum). Selec-
tion of the contemporaneous 278 consecutive control pa-
tients whose crossmatch test results were negative when less 
than 10% of donor lymphocytes were killed. and were 
doubtfully or weakly positive when II % to 49% of donor 
lymphocytes were killed. None of the 306 patients received 
ABO blood group-incompatible grafts. All donor livers 
were preserved by University of Wisconsin solution. 
The study groups differed in crossmatch status. negative 
control (group l,1Z = 278) and positive group (group 2.11 = 
28). There was a generally high degree of illness in both the 
positive crossmatch group and their controls. as defined by 
the United Network for Organ Sharing (UNOS) stratifica-
tion (Table I). 
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Table 1. Patients' Profile 
Groups 
1 (II = 278) 2(11=28) 
Crossmatch Status Negative Positive 
Age 47 (17-75) 53 (33-66) 
Male/Female 178/100 10118' 
UNOS score (mean)t 3.5:!: 0.5 3.7:!: 0.5 
UNOS4 78 ] ~P ] 75% UNOS 4 us 89 60% 
Cold ischemic time (h) 15.8 :!: 3.9 14.8 :!: 0.7 
Preservation solution UW solution UW solution 
'p < .01 vs group 1. 
tMean::!: SO. 
The Crossmatch Test 
Each recipient's serum was drawn immediately before and 
after liver transplantation and tested for cytotoxic cross-
matching activity before and after treatment with dithio-
threitol (DTT), which inactivates IgM antibodies.9 Donor T 
lymphocytes isolated from lymph nodes using CD3-conju-
gated dynabeads (Dynal, Great Neck. NY) were used. 
The cytotoxicity test was performed according to Na-
tional Institutes of Health standards with one wash; 1 ILL of 
2 x 106 mL T lymphocytes was placed into 1 ILL of serum, 
followed by a I-hour incubation at room temperature. The 
liter of antibodies present was determined by a 1:2 serial 
dilution of the sera with RPMI 1640. Aiter one wash, 
addition of 5 ILL of rabbit complement for I-hour at room 
temperature produced lysis that was evaluated using trypan 
blue exclusion. Crossmatch test results were positive when 
50% to 79% of donor lymphocytes were killed and were 
strongly positive when more than 80% of lymphocytes were 
killed by DIT-pretreated recipient serum. 
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Immunosuppression 
Between November 1989 and May 1990. intravenous (IV) 
doses of 0.15 mg/kg of FK 506 in divided dosage were 
infused over 3 to 4 hours, starting in the operating room. 
Then, the basement immunosuppression was changed from 
June 1990 to 0.1 mg/kg to 24 hours' continuous infusion, 
and repeated every 24 hours until oral intake began. The 
conversion from IV to oral doses of 0.15 mg/kg every 12 
hours was overlapped for 1 day. 
Usually, 1 g of IV methylpredonisolone was given after 
reperfusion. A daily dose of 20 mg methylpredonisolone 
was started after the operation; the dosage was tapered 
later in all patients. 
Rejection episodes proven by liver biopsy were treated 
first with a single 1-g bolus of methylpredonisolone. If 
rejection persisted. the patient received an additional 5-day 
burst of methylpredonisolone (steroid recycle) or a 3-5 day 
course of 5 to 10 mg/d of OKT3. 
Follow-up Period 
The follow-up period was to December 31. 1997, or until 
death. A median follow-up was 7.7 years. and a minimum 
follow-up was 7.2 years. 
Statistical Analysis 
The chi-square analysis was used to compare the incidence 
of acute rejection, ischemic injury, bile duct complications, 
and chronic rejection in both groups. Graft survival was 
determined by the Kaplan-Meier method. 
The diagnosis of bile duct complications was according to 
the protocol with ultrasonography. tube or percutaneous 
cholangiography to evaluate the causes of cholestatic graft 
dysfunction and hepatic chemicals. Finally, liver biopsy was 
performed at the time of graft dysfunction. The diagnosis of 
chronic rejection was based upon histological findings of 
disappearing interlobular bile ducts with scant mononuclear 
portal infiltrates, progressing later to bridging fibrosis with 
large, expanded portal tracts. 10.1 I 
RESULTS 
There was no difference in patients' profiles of both groups 
except the ratio of male/female patients. The incidence of 
female patients was higher in positive crossmatch cases 
when compared with controls (36% in group 1 vs 64% in 
group 2. P < .01. Table 1). Twenty-six of 28 (92.9%) group 
2. patients were strongly positive crossmatch results. which 
represent more than 80% of the donor lymphocytes killing 
against rccipients' sera in DTT treatment. High titers of the 
antibodies (more than l:8 dilution of a recipient's serum) 
were detected in 15/28 (53.6'1C) of all positive crossmatch 
patients. 
The actuarial graft survival at 6 months was significantly 
lower in group 2 patients compared with those of group 1 
controls (60.7% vs 84.8%. P < .1l01). 
This study. examining hile duct complications and 
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Table 2. Bile Duct Complications in Negative Control Group 1 
Patients (Clinico-Pathological Diagnosis)" 
Complication 
Biliary obstruction obstruction with cholangitis 
Biliary stricture 
Bile leak 
Bile duct stricture following hepatic artery 
thrombosis 
Stricture of the choledochojejunostomy 
Bile cast syndrome 
Biliary fistula 
Total 
N 
9 (38-2400 days) 
7 (19-987 days) 
3 (37-93 days) 
2 (261 ;661 days) 
2 (265;364 days) 
1 (374 days) 
1 (112 days) 
25/245 (10.2%) 
'Patients whose first grafts had not failed within 3 months. 
chronic rejection, was undertaken in patients whose first 
graft had not failed within 3 months after orthotopic liver 
transplantation (OLTX) in both groups (245 cases in group 
1 and 19 cases in group 2). 
The incidence of major bile duct complications was 
developed in 10.2% (25/245) of group I negative control 
patients (Table 2). Bile duct obstruction and/or obstruction 
with cholangitis was observed in nine cases as a major bile 
duct complication. Biliary strictures were observed in seven 
cases, Bile leak, bile duct stricture following hepatic artery 
thrombosis. stricture of the choledochojejunostomy, and 
biliary fistula were observed as shown in Table 2 of group 1 
patients. 
Conversely, the incidence of major bile duct complication 
was significantly high (36.8%, 7119, P < .005) in group 2 
patients with the interval of 89 to 664 days after OLTX 
when compared to group 1 patients (Table 3). In seven 
cases of major bile duct complications in group 2 patients, 
bile duct obstruction and/or obstruction with cholangitis 
was observed in four cases of group 2 (57,1%. 4/7). The 
others consisted of one case of multiple biliary strictures 
with ongoing intrahepatic portal thrombi (retransplanted 
on day 95), one case of biliary stricture and revision (849 
days), and one case of focal necrosis of the bile duct and 
cholestasis (374 days) (Table 4). Additionally, two more 
positive crossmatch patients experienced late severe vascu-
lar complications: one had a portal vein thrombosis on day 
582 and was retransplanted: another one had a mycotic 
aneurysm of the hepatic artery on day 245 after OL TX. 
Chronic rejection was diagnosed on the basis of patho-
Table 3. Incidence of Bile Duct Complications in Both Group 1 
and Group 2 Patients 
Groups 
2 
Crossmatch Status Negative Positive 
Patients whose first grafts had 
not failed Within 3 months 245 19 
Incidence of bile duct 25 (10.2%) 7 (36.8%)' 
complications 
Interval (days after OL Tx) 10-2400 days 89-664 days 
'p ~ .005 vs group 1 In Chi-square analYSIS. 
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Table 4. Bile Duct Complications in Positive Crossmatch 
Group 2 Patients (elinico-Pathological Diagnosis)" 
Complication 
Biliary obstruction 
Multiple biliary strictures with ongoing 
intrahepatic portal thromb 
Biliary stricture and revision 
Focal necrosis of the bile duct cholestasis 
Total 
N 
4 (89-1142 days) 
1 (95 days) 
1 (849 days) 
1 (374 days) 
7/19 (36.8%) 
'Patients whose first grafts had not failed within 3 months. 
logical biopsy reports with the importance of assessing 
findings over time rather than assessing a single needle core 
in the ultimate prognosis. In principle, the histopathology of 
the chronic rejection was duct loss, portal fibrosis, and 
arteriolar thickening of the graft. 
Biopsy-proven chronic rejection was observed in 12 cases, 
with an interval of 185 to 1687 days in group 1 negative 
control patients (4.9%, 12/245). One patient was retrans-
planted on day 2130 and was, respectively, dead on day 
2148. Two patients died on days 646 and 2009, after OLTX. 
Only three grafts (1.1%, 3/278) were lost due to chronic 
rejection. In contrast, chronic rejection was observed in five 
cases out of 19 patients, with an interval of 125 to 709 days 
after OLTX in group 2 positive crossmatch patients (26.3%, 
5/19). The incidence of chronic rejection was significantly 
higher than those of negative control group 1 patients 
(26.3% vs 4.9%, P < .005, Table 5). In the five positive 
crossmatch patients who had a diagnosis of chronic rejec-
tion, one patient was retransplanted on day 126 and died on 
day 141. Also, two patients died on days 95 and 1368, 
respectively, after OLTX. Three grafts in group 2 positive 
crossmatch patients were lost by chronic rejection (10.7%, 
3/28). 
DISCUSSION 
The adverse effect of preformed antibody states on the 
transplanted liver has been increasingly acknowl-
edged.7,12,13 First was the recognition of the poor prognosis 
if an ABO-incompatible donor was used 14,15; second. an 
increased graft loss in the early phase after liver transplan-
tation was noted in positive cytotoxic crossmatch cases. 13 
However. the impact of lymphocytotoxic antibodies as 
the cause of humoral rejection after liver transplantation 
Table 5. Incidence of Chronic Rejection in Both Group 1 and 
Group 2 Patients· 
Crossmatch 
Patients whose first grafts had 
not failed within 3 months 
Incidence of chrOniC rejection 
Interval (days after OL Tx) 
Groups 
Negative 
245 
12 (4.9%) 
185-1687 days 
2 
Positive 
19 
5 (26.3%)1 
125-709 days 
'Duct loss. ponal fibrOSIS, and artel'1olar thickening In pathological findings. 
tp < .005 vs group 1 In chi-square analYSIS . 
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has been confused in the past because of several factors. 
One factor has been the selection and sensitivity of cross-
match technique. The critical issues that must be decided 
are which antibodies need to be considered in liver trans-
plantation-IgG, T cell, B cell, HLA class I or HLA class II, 
anti-endothelial cell. In this series we used the test for 
cytotoxic antibody activity against T lymphocytes isolated 
from donor lymph nodes at room temperature (37"C) , 
followed by a 60 minute incubation period with rabbit 
complement. If the screening test was positive, the recipient 
serum was pretreated with DTT to inactivate the IgM 
antibodies. Only two cases out of 28 group 2 patients 
changed from positive reactivities to positive ones after 
DTT treatment. 
In this study, we showed a high incidence of bile duct 
complications in the presence of a cytotoxic crossmatch 
group. These biliary complications involve only the donor 
biliary tree and lead to significant morbidity, the same as 
the ABO-incompatible group.16 Although the results of our 
study imply an immune-mediated pathogenesis, the precise 
mechanism remains unclear. However, the acute injury 
appears to be related to mechanical occulusion of micro-
vasculature/7 and functional narrowing of the arterial tree 
because of immunologically mediated vasoconstriction has 
been reportedY This injury can manifest as focal intrahe-
patic infarcts and bile duct necrosis followed later by 
periductal fibrosis and stricturing. Because of a dual blood 
supply, which may be one of the causes of resistance to 
antibody-mediated rejection, the biliary tree may injure 
because of its arterial-only-type circulation and more con-
ventional arteriolar and capillary networkY·17 
The incidence of chronic rejection in the positive cross-
match group, which survived more than 3 months after 
OL TX. was significantly higher than those of negative cases 
in this series. However. recent reports do not support these 
observations,7,8 This may be due to the differences of the 
sensitivity of the crossmatch test, and differences of the 
basic immunosuppression regimens. Antibodies to non-
HLA target antigens may be important. Immunoglobulin 
deposition on biliary epithelium and vascular endothelial 
cells has been reported in chronic rejection of liver trans-
plants. 1 1.18.19 
Ever since we recognized the increased immunology risk, 
we routinely include high-dose steroids (1 g methylpre-
donisolone) immediately after reperfusion and so-called 
steroid recycle starting postoperative day 1 andlor antileu-
kocyte antibodies after this time period.lo 
The etiology of transplant obstructive arteriopathy or 
chronic rcjection is still unknown. Bile duct injury and 
chronic rejection may be related to the vasculopathy that is 
accelerated by chemokines. cytokines. and growth factors 
released from T lymphocytes and antigen-presenting mac-
rophages. vascular smooth muscle cells. and endothelial 
cellsKO1K~l Further molecular studies of these mechanisms 
should be investigated to settle the question of the patho-
genesis of chronic rejection. 
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CONCLUSION 
We investigated the outcome of liver allografts from 
positive crossmatch donors. focusing on biliary complica-
tions and ductopenic chronic rejection. and we compared 
the results to a negative crossmatch control group. 
2. The major biliary complication developed in 36.8% of 
positive crossmatch patients. compared to 10.2% of 
negative controls. 
3. Chronic rejection was observed in 26.3% of positive 
crossmatch patients, and 4.9% of negative control 
patients. Significantly high incidences of ischemic in-
juries were observed in all liver biopsy specimens of 
positive crossmatch patients compared to those of 
negative controls. 
Finally. an immunologic injury to the bile duct epithelium 
or a bile duct injury due to the reduction of periductal blood 
supply secondary to the vascular endothelial damage is 
suspected. 
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